“A two-year activity evaluate of more than 80 proportionality in continual or disobedient anaplastic astrocytoma suggests a insight in this disrespectful disease by targeted therapy,” commented Prof. Ulrich Bogdahn, Neuro-Oncologist and Coordinating Investigator of the Phase IIb active-controlled dose-finding effort with AP 12009 in continual or disobedient high-grade glioma, patch presenting the accumulation at the 44th Annual Meeting of the dweller Society of Clinical Oncology (ASCO) in Chicago, USA, today. (Source: Neurology / Neuroscience News From Medical News Today)

Tags: Annual Meeting, Current, glioma, Led, Survival Rate